Wet age-related macular degeneration

Inclusion Criteria

- A diagnosis of wAMD.
- Patients for whom the decision to initiate treatment with IVT aflibercept in a proactive regimen was made as routine clinical practice.
- Treatment-naïve in the study eye (no prior therapy for wAMD).
- Patient age ≥50 years of age.
- Written informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).

Exclusion Criteria

- Participation in an investigational program with interventions outside of routine clinical practice.
- Patients with contraindications to IVT aflibercept listed in the local marketing authorization.
- Planned treatment regimen outside of the local marketing authorization.
- Patients with eye diseases, e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye.
- Concomitant ocular or systemic administration of drugs up to 3 months before IVT aflibercept treatment that could interfere with or potentiate the mechanism of action of IVT aflibercept, including other anti-VEGF agents in the fellow eye.
- Any other retinal disease which may interfere with the treatment of wAMD.